FDA tags Bayer's prostate cancer drug for priority review as drugmaker gears up against rivals

Two months after Bayer and its Finnish partner Orion reported positive late-stage data for its prostate cancer drug darolutamide, the German drugmaker has convinced the FDA to grant priority review on its NDA.